Back to News
Market Impact: 0.38
X4 Pharma Reports Positive Outcome Of Type C Meeting With FDA Related To 4WARD Phase 3 Trial
Source: Nasdaq
Healthcare & BiotechRegulation & LegislationCorporate Guidance & Outlook
X4 Pharmaceuticals announced a positive Type C meeting outcome with the FDA regarding its global 4WARD Phase 3 clinical trial. The meeting aligned the company and regulator on a revised trial sample size, associated statistical power, and safety-database size, reducing regulatory uncertainty around the study design and supporting the program's development path.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.58
Ticker Sentiment
XFOR0.72
More News
- What next for France as riots rattle markets? Three questions facing investors ahead of more protests
- Looters hit 3,000 French businesses. Within hours, the haul was trending on Vinted under the riot’s date
- Vertex reports positive IgAN trial data, FDA decision due Nov. 30
- The real test for Moderna’s cancer vaccine isn’t about beating Keytruda. It’s keeping cancer from coming back in the long term.
- With earnings in rearview mirror, SpaceX-Tesla merger chatter takes center stage
- J&J prostate cancer drug shows promising tumor responses in early trial